Form 4: Guardant Health Executive Chris Freeman Reports Stock Transactions

Chief Commercial Officer Chris Freeman reports acquisition and disposal of Guardant Health stock and restricted stock units due to vesting and tax obligations.

Summary

• Chris Freeman, Chief Commercial Officer of Guardant Health, reported transactions involving the company's stock on June 15, 2024.
• These transactions include the acquisition of 4,879 and 5,523 shares of common stock through the vesting of restricted stock units.
• Freeman also disposed of 2,870 shares to cover tax withholding obligations related to the vesting of these units at a price of $30.21 per share.
• Following these transactions, Freeman directly owns 24,599 shares of Guardant Health common stock.
• Additionally, Freeman holds 4,879 and 11,215 restricted stock units.
• Table I includes 1,096 shares acquired under Guardant Health's Employee Stock Purchase Plan on 5/14/2024.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The filing reflects routine transactions related to executive compensation and tax obligations, with no clear positive or negative implications for the company's outlook.

Positives

• The vesting of restricted stock units indicates a continued alignment of the executive's interests with the company's performance.

Negatives

• The disposal of shares to cover tax obligations, while standard, slightly reduces the executive's direct holdings.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. These filings are closely watched by investors seeking insights into management's perspective on the company's stock.

Comparison to Industry Standards

• Executive compensation packages often include restricted stock units that vest over time, aligning executive interests with long-term shareholder value.
• The practice of selling shares to cover tax obligations upon vesting is a common occurrence among executives at publicly traded companies.
• Similar transactions are regularly reported by executives at companies like Exact Sciences and Illumina, which are also in the cancer diagnostics space.

Stakeholder Impact

• The transactions have a minimal direct impact on shareholders, as they primarily reflect internal compensation mechanisms.
• Employees holding stock options or restricted stock units may find the information useful for understanding the tax implications of vesting.

Key Dates